- Home
- FRPH vs ATAI Comparison
FRPH vs ATAI Comparison
Compare FRPH & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRPH
- ATAI
- Stock Information
- Founded
- FRPH 1986
- ATAI 2018
- Country
- FRPH United States
- ATAI Germany
- Employees
- FRPH N/A
- ATAI N/A
- Industry
- FRPH Real Estate
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- FRPH Finance
- ATAI Health Care
- Exchange
- FRPH Nasdaq
- ATAI Nasdaq
- Market Cap
- FRPH 537.7M
- ATAI 444.7M
- IPO Year
- FRPH N/A
- ATAI 2021
- Fundamental
- Price
- FRPH $26.76
- ATAI $2.48
- Analyst Decision
- FRPH
- ATAI Strong Buy
- Analyst Count
- FRPH 0
- ATAI 3
- Target Price
- FRPH N/A
- ATAI $10.50
- AVG Volume (30 Days)
- FRPH 49.6K
- ATAI 2.7M
- Earning Date
- FRPH 08-06-2025
- ATAI 08-12-2025
- Dividend Yield
- FRPH N/A
- ATAI N/A
- EPS Growth
- FRPH 12.32
- ATAI N/A
- EPS
- FRPH 0.36
- ATAI N/A
- Revenue
- FRPH $31,576,000.00
- ATAI $1,863,000.00
- Revenue This Year
- FRPH N/A
- ATAI $554.22
- Revenue Next Year
- FRPH N/A
- ATAI N/A
- P/E Ratio
- FRPH $74.46
- ATAI N/A
- Revenue Growth
- FRPH 4.58
- ATAI 572.56
- 52 Week Low
- FRPH $25.37
- ATAI $1.03
- 52 Week High
- FRPH $33.00
- ATAI $2.64
- Technical
- Relative Strength Index (RSI)
- FRPH 45.67
- ATAI 66.50
- Support Level
- FRPH $26.74
- ATAI $2.06
- Resistance Level
- FRPH $27.98
- ATAI $2.55
- Average True Range (ATR)
- FRPH 0.61
- ATAI 0.20
- MACD
- FRPH -0.03
- ATAI -0.02
- Stochastic Oscillator
- FRPH 3.73
- ATAI 72.41
About FRPH FRP Holdings Inc.
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.